Phase I Study of Recombinant CEA Vaccinia Virus Vaccine with Post Vaccination CEA Peptide Challenge. Medical University of South Carolina, Charleston, South Carolina
- 10 July 1996
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 7 (11) , 1381-1394
- https://doi.org/10.1089/hum.1996.7.11-1381
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus VaccineJNCI Journal of the National Cancer Institute, 1992
- Cancer statistics, 1992CA: A Cancer Journal for Clinicians, 1992
- A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA)International Journal of Cancer, 1991
- Safety of recombinant vaccinia vaccinesThe Lancet, 1991
- Vaccinia Virus Expression VectorsAnnual Review of Immunology, 1987
- Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequenceBiochemical and Biophysical Research Communications, 1986
- Cea-related antigens: Molecular biology and clinical significanceCritical Reviews in Oncology/Hematology, 1985
- Expression of rabies virus glycoprotein from a recombinant vaccinia virusNature, 1984
- Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cellsNature, 1984
- Infectious vaccinia virus recombinants that express hepatitis B virus surface antigenNature, 1983